- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01555502
Health Related Quality of Life After Video Assisted Thoracoscopic Lobectomy for Lung Cancer
To test the effect of post operative complications on the health related quality of life (HRQOL) after Video Assisted Thoracoscopic Surgery (VATS) for Non-Small Cell Lung Cancer (NSCLC).
The HRQOL of patients with early stage NSCLC will be assessed at baseline (before surgery) using 3 different reliable and valid HRQOL questionnaire (SF-36, EQ-5D and QLQ30/13), then at regular intervals in the early post-operative period (2,4,8 and 12 weeks) the HRQOL will be assessed using the same questionnaires to determine the difference between patients with low/no post operative complications to those with high grade post-operative complications.
Post operative complications will be assess while the patients in the hospital on a daily basis using the Clavien classification system for surgical complications.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T5H 3V9
- Royal Alexandra Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (more than 18 years)
- early stage NSCLC
- speak English
- No hearing/Speaking difficulties
- Able to walk without assistance
- Surgery via the VATS approach
Exclusion Criteria:
- Less than 18 years old
- Metastatic disease to the lung
- Benign Lung disease
- Advanced NSCLC
- Small Cell Lung Cancer
- Non English speakers
- Walking/Hearing/Speaking difficulties
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
low complications
Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
|
|
High complications
Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health related Quality of life
Time Frame: Change in health related quality of life at 2 weeks. Change of Health Related Quality of Life at 4 weeks. Change in Health Related Quality of Life at 8 weeks. Change in Health Related Quality of Life at 12 weeks.
|
Health Related Quality of Life will be assessed using the SF-36, EQ-5D and QLQ30/13 questionnaires.
|
Change in health related quality of life at 2 weeks. Change of Health Related Quality of Life at 4 weeks. Change in Health Related Quality of Life at 8 weeks. Change in Health Related Quality of Life at 12 weeks.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HRQOL VATS lobectomy
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Operable Early Stage NSCLC by the VATS Approach
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
Taiho Oncology, Inc.Active, not recruitingLung Cancer | Adjuvant | EGFR | NSCLC, Stage IB-IIIA | Post-surgical | Exon 20 | Early Stage Lung Cancer | Uncommon EGFR MutationsSpain, United States, Canada, Japan, Malaysia, Belgium, Italy, Australia, Thailand, Brazil, Hong Kong, France, United Kingdom, Argentina, Netherlands, Romania, Singapore, Mexico, South Korea, Germany, Turkey (Türkiye), Greece, Peru, P...
-
TriHealth Inc.TriHealth Hatton Research Institute; Bethesda North Hospital FoundationTerminatedEarly Stage Breast Cancer | Breast Tumor | Neoplasm of the BreastUnited States
-
Beijing Chao Yang HospitalRecruitingNSCLC | Pulmonary Nodule | Early-Stage Lung CancerChina
-
MedImmune LLCCompletedNSCLC | Resectable | Early-stageUnited States, Canada, Switzerland, Italy, France, Portugal, Spain
-
Guangzhou Institute of Respiratory DiseaseThe First Affiliated Hospital of Anhui Medical University; Fuda Cancer Hospital... and other collaboratorsActive, not recruitingLung Cancer (NSCLC) | Early Stage Lung Non-Small Cell CarcinomaChina
-
AmgenActive, not recruitingEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)Spain, Germany, Taiwan, France, Philippines, Malaysia, Georgia, Bulgaria, Italy, Romania, Poland, Turkey (Türkiye), South Korea, Argentina, Serbia, Thailand, Chile, Mexico
-
Lawson Health Research InstituteActive, not recruitingEarly-Stage Squamous Cell Carcinoma of the OropharynxCanada, Australia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedCervical Intraepithelial Neoplasia | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Vaginal Adenocarcinoma | Vulvar Intraepithelial Neoplasia | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical... and other conditionsUnited States